Should You Buy the Dip on Broadcom Stock?

Broadcom’s AI semiconductor revenue rose 143% year over year to $10.8 billion in fiscal Q2, and management guided for 200% growth to $16 billion in Q3, with the AI business still expected to exceed $100 billion in annual revenue by 2027. The stock sold off nearly 20% from its all-time high after earnings because the market had priced in even faster growth, with the shares previously trading around 40x forward earnings. The article argues the pullback may create a buying opportunity, though expectations remain elevated.

Analysis

The selloff looks less like a fundamental break and more like a valuation reset in a name that had become the cleanest public-market proxy for AI capex momentum. The key second-order issue is that AVGO is now priced as a quarterly “beat-and-raise or die” asset, so even strong growth can underwhelm if the rate of acceleration no longer improves. That creates a path dependency: the stock likely trades more on incremental evidence of 2027-2030 demand durability than on near-term revenue prints.

The competitive dynamic is subtle: custom silicon is a share-grab from merchant GPU ecosystems, but it also depends on the health of those ecosystems to justify hyperscaler spend. If hyperscalers slow AI capex or rebalance toward inference efficiency, AVGO’s custom chips may be more resilient than NVDA’s high-end training demand, yet the broader AI supply chain could de-rate together. In that sense, AVGO is a beneficiary of AI localization, but also a hostage to whether customers keep building proprietary stacks instead of standardizing.

The contrarian miss is that this is not a simple “cheap after the dip” setup; the stock can stay range-bound until the market gets a new catalyst beyond the same long-duration TAM story. The most important horizon is months, not days: if the next 1-2 quarters show reacceleration in backlog or customer concentration broadening, the multiple can stabilize. If not, 20x 2027 earnings is still vulnerable to further compression because the market is implicitly discounting execution risk, not just growth.

From a positioning standpoint, the more interesting trade is relative value versus NVDA rather than outright longs. AVGO’s mix of custom chip visibility and software cash flow should make it less beta-sensitive than pure AI semis, but that premium only works if investors trust the durability of 2027+ guidance. Otherwise, the stock risks becoming a capital allocation story rather than an AI winner story, which would cap upside until the next major guide-up.

Key Decisions for Investors

• Keep AVGO on a tactical hold/accumulate list, but only on further weakness or after the next earnings window; risk/reward improves if the stock de-risks another 5-10% while fundamentals remain intact.
• Relative-value trade: long AVGO / short NVDA for the next 1-2 quarters if the market continues to punish any AI multiple compression; thesis is AVGO has better visibility into proprietary demand and a less crowded ownership base.
• If already long AVGO, hedge with short-dated calls or a collar into the next print; the setup is sensitive to any pause in guidance acceleration, and upside may be capped until the market sees a fresh catalyst.
• Watch for evidence of customer diversification and deployment cadence over the next 2 quarters; if AI semiconductor revenue growth stays above 100% but guidance does not step higher, reduce exposure because the multiple can compress further.
• Avoid chasing the move in NVDA off this headline alone; AVGO’s read-through is more about AI capex quality than broad industry upside, so use it as a confirmation signal rather than an outright sector bullish trigger.